Physician profile
Brian Benson
NPI 1740574870
$2,570.16
in general payments reported to CMS, 2019-2025
18 companies · $1,599 in 2025
The $1,599 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $972 · 2025: $1,599.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,570.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,570.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $374.99 | 2024-2025 | |
| Ipsen Biopharmaceuticals, INC | $258.82 | 2024-2025 | Iqirvo, Bylvay |
| Gilead Sciences, INC. | $243.07 | 2024-2025 | |
| Janssen Biotech, INC. | $204.62 | 2024-2025 | Tremfya, Stelara |
| Phathom Pharmaceuticals, INC. | $179.89 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $161.28 | 2024-2025 | Rezdiffra, Resmetirom |
| Qol Medical, LLC | $143.55 | 2025 | Sucraid |
| Steris Corporation | $141.55 | 2024 | |
| Pfizer INC. | $126.27 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $123.35 | 2024-2025 | Entyvio, Eohilia |
| E.R. Squibb & Sons, L.L.C. | $119.70 | 2024 | |
| Braintree Laboratories, INC. | $107.44 | 2025 | Suflave, Sutab |
| Ardelyx, INC. | $104.43 | 2024-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $67.65 | 2024-2025 | Dupixent |
| Celgene Corporation | $63.82 | 2024 | Zeposia |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $53.89 | 2025 | Zenpep |
| Genzyme Corporation | $52.82 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.02 | 2025 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Benson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.